Your session is about to expire
← Back to Search
Cholinesterase Inhibitor
Echothiophate Iodide for Near-sightedness
Phase 4
Waitlist Available
Led By Stephen A Mathias, MD, MPH
Research Sponsored by Danbury Eye Physicians & Surgeons, PC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks
Awards & highlights
Study Summary
The purpose of this study is to test the hypothesis that myopia progression can be slowed or prevented by low dose Echothiophate Iodide.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 12 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Refractive Errors
Secondary outcome measures
Axial Length
Choroiditis
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: Echothiophate IodideExperimental Treatment1 Intervention
Echothiophate Iodide 0.03% one drop to each eye three times per week for 18 weeks
Group II: Carboxymethylcellulose Sodium (0.5%)Placebo Group1 Intervention
Carboxymethylcellulose Sodium (0.5%) one drop to each eye three times per week for 18 weeks
Find a Location
Who is running the clinical trial?
Danbury Eye Physicians & Surgeons, PCLead Sponsor
Stephen A Mathias, MD, MPHPrincipal InvestigatorDanbury Eye Physicians & Surgeons, PC
Share this study with friends
Copy Link
Messenger